Development of a chimeric replicon system for phenotypic analysis of NS3 protease sequences from HCV clinical isolates

Antiviral Therapy

Volumn 16, Issue 5, 2011, Pages 705-718

  Sheaffer, Amy K ^a   Lee, Min S ^a   Hernandez, Dennis ^a   Chaniewski, Susan ^a   Yu, Fei ^a   Falk, Paul ^a   Friborg, Jacques ^a   Zhai, Guangzhi ^a   McPhee, Fiona ^a  

^a BRISTOL MYERS SQUIBB   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

NONSTRUCTURAL PROTEIN 3 PROTEASE; NONSTRUCTURAL PROTEIN 3 PROTEASE INHIBITOR; PROTEINASE; PROTEINASE INHIBITOR; UNCLASSIFIED DRUG; VIRUS RNA;

AMINO ACID SEQUENCE; ARTICLE; CELL CULTURE; CHIMERA; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG SENSITIVITY; ENZYME ACTIVITY; EVOLUTIONARY ADAPTATION; GENETIC CORRELATION; GENETIC POLYMORPHISM; GENOTYPE; HEPATITIS C VIRUS; NONHUMAN; PHENOTYPIC VARIATION; PRIORITY JOURNAL; PROTEIN DOMAIN; REPLICON; SHUTTLE VECTOR; VIRUS DETECTION; VIRUS ISOLATION; VIRUS REPLICATION; VIRUS RESISTANCE; VIRUS STRAIN;

ANTIVIRAL AGENTS; DRUG RESISTANCE, VIRAL; GENETIC VECTORS; GENOTYPE; HEPACIVIRUS; HUMANS; MUTANT CHIMERIC PROTEINS; PHENOTYPE; PLASMIDS; PROTEASE INHIBITORS; REPLICON; SENSITIVITY AND SPECIFICITY; VIRAL NONSTRUCTURAL PROTEINS;

EID: 80052506992     PISSN: 13596535     EISSN: None     Source Type: Journal    
DOI: 10.3851/IMP1825     Document Type: Article

References (34)

1. Choo Q.L., Kuo G., Weiner A.J., et al. Isolation of a cDNA clone derived from a blood-borne non-A, non-B viral hepatitis genome. Science 1989; 244:359-362. (Pubitemid 19117877)
2. Lavanchy D. The global burden of HCV. Liver Int 2009; 29:74-81.
3. Foster G.R. Quality of life considerations for patients with chronic hepatitis C. J Viral Hepat 2009; 16:605-611.
4. Manns M.P., McHutchison J.G., Gordon S.C., et al. Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: A randomised trial. Lancet 2001; 358:958-965. (Pubitemid 32913521)
5. Fried M.W., Shiffman M.L., Reddy R., et al. Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection. N Engl J Med 2002; 347:975-982.
6. Kwong A.D., McNair L., Jacobson I., et al. Recent progress in the development of seleted hepatitis C virus NS3-4A protease and NS5B inhibitors. Curr Opin Pharmacol 2008; 8:522-531.
7. Hézode C., Forestier N., Dusheiko G., et al. Telaprevir and peginterferon with or without ribavirin for chronic HCV infection. N Engl J Med 2009; 360:1839-1850.
8. Sarrazin C., Rouzier R., Wagner F., et al. SCH 503034, a novel hepatitis C virus protease inhibitor, plus pegylated interferon &αλπ ηα;-2b for genotype 1 nonresponders. Gastroenterology 2007; 132:1270-1278. (Pubitemid 46627577)
9. Susser S., Welsch C., Wang Y., et al. Characterization of resistance to the protease inhibitor boceprevir in hepatitis C virus-infected patients. Hepatology 2009; 50:1709-1718.
10. López-Labrador F.X., Moya A., Gonzàlez-Candelas F. Mapping natural polymorphisms of hepatitis C virus NS3/4A protease and antiviral resistance to inhibitors in worldwide isolates. Antivir Ther 2008; 13:481-494. (Pubitemid 352016711)
11. Cubero M., Esteban J.I., Otero T., et al. Naturally occurring NS3-protease-inhibitor resistant mutant A156T in the liver of an untreated chronic hepatitis C patient. Virology 2008; 370:237-245. (Pubitemid 350192568)
12. Kuntzen T., Timm J., Berical A., et al. Naturally occurring dominant resistance mutations to hepatitis C virus protease and polymerase inhibitors in treatment-naive patients. Hepatology 2008; 48:1769-1778.
13. Bartels D.J., Zhou Y., Zhang E.Z. Natural prevalence of hepatitis C virus variants with decreased sensitivity to NS3.4A PIs in treatment-naive subjects. J Infect Dis 2008; 198:800-807.
14. Wakita T., Pietschmann T., Kato T., et al. Production of infectious hepatitis C virus in tissue culture from a cloned viral genome. Nat Med 2005; 11:791-796. (Pubitemid 41021213)
15. Lindenbach B.D., Evans M.J., Syder A.J., et al. Complete replication of hepatitis C virus in cell culture. Science 2005; 309:623-626. (Pubitemid 41033648)
16. Yi M., Villanueva R.A., Thomas D.L., et al. Production of infectious genotype 1a hepatitis C virus (Hutchinson strain) in cultured human hepatoma cells. Proc Natl Acad Sci U S A 2006; 103:2310-2315. (Pubitemid 43271666)
17. Bartenschlager R., Sparacio S. Hepatitis C virus molecular clones and their replication capacity in vivo and in cell culture. Virus Res 2007; 127:195-207. (Pubitemid 47058197)
18. Qi X., Bae A., Liu S., et al. Development of a replicon-based phenotypic assay for assessing the drug susceptibilities of HCV NS3 protease genes from clinical isolates. Antiviral Res 2009; 81:166-173.
19. Lemm J.A., Liu M., Rose R.E., et al. Replication-competent chimeric hepatitis C virus subgenomic replicons. Intervirology 2005; 48:183-191. (Pubitemid 41201509)
20. Drexler D., Barlow D.J., Falk P., et al. Development of an on-line automated sample clean-up method and liquid chromatography-tandem mass spectrometry analysis: Application in an in vitro proteolytic assay. Anal Bioanal Chem 2006; 384:1145-1154. (Pubitemid 43333996)
21. Yanagi M., Purcell R.H., Emerson S.U., et al. Transcripts from a single full-length cDNA clone of hepatitis C virus are infectious when directly transfected into the liver of a chimpanzee. Proc Natl Acad Sci U S A 1997; 94:8738-8743. (Pubitemid 27335109)
22. Krieger N., Lohmann V., Bartenschlager R. Enhancement of hepatitis C virus RNA replication by cell culture adaptive mutations. J Virol 2001; 75:4614-4624. (Pubitemid 32381503)
23. Verbeeck J., Stanley, M.J., Shieh J., et al. Evaluation of versant hepatitis C virus Gt assay (LiPA) 2.0. J Clin Microbiol 2008; 46:1901-1906. (Pubitemid 351831817)
24. Kuiken C., Yusim K., Boykin L., et al. The Los Alamos HCV sequence database. Bioinformatics 2005; 21:379-384. (Pubitemid 40246609)
25. Sarrazin C., Kieffer T.L., Bartels D., et al. Dynamic hepatitis C virus genotypic and phenotypic changes in patients treated with the protease inhibitor telaprevir. Gastroenterology 2007; 132:1767-1777. (Pubitemid 46677938)
26. Zhou Y., Muh U., Janzelka B.L., et al. Phenotypic and structural analyses of hepatitis C virus NS3 protease Arg155 variants: Sensitivity to telaprevir (VS-950) and interferon alpha. J Biol Chem 2007; 282:22619-22628. (Pubitemid 47267330)
27. McPhee F., Good A.C., Campbell J.A., et al. Discovery and early development of the HCV NS3 protease inhibitor BMS- 605339. HepDART. 6-10 December 2009, Kohala Coast, HI, USA. Abstract 55.
28. Imhof I., Simmonds P. Development of an intergenotypic hepatitis C virus cell culture method to assess antiviral susceptibilities and resistance development of HCV NS3 protease genes from HCV genotypes 1 to 6. J Virol 2010; 84:4597-4610.
29. Lin C., Lin K., Luong Y.P., et al. In vitro resistance studies of hepatitis C virus serine protease inhibitors, VX-950 and BILN 2061: Structural analysis indicates different resistance mechanisms. J Biol Chem 2004; 279:17508-17514. (Pubitemid 38560514)
30. Thibeault D., Bousquet C., Gingras R., et al. Sensitivity of NS3 serine proteases from hepatitis C virus genotypes 2 and 3 to the inhibitor BILN-2061. J Virol 2004; 78:7352-7359. (Pubitemid 38915881)
31. Lenz O., Verbinnen T., Lin T-I, et al. In vitro resistance profile of the hepatitis C virus NS3/4A protease inhibitor TMC435. Antimicrob Agents Chemother 2010; 54:1878-1887.
32. Chase R., Skelton A., Xia E., et al. A novel HCV NS3 protease mutation selected by combination treatment of the protease inhibitor boceprevir and NS5B polymerase inhibitors. Antiviral Res 2009; 84:178-184.
33. McCown M.F., Rajyaguru S., Le Pogam S., et al. The hepatitis C virus replicon presents a higher barrier to resistance to nucleoside analogs than to nonnucleoside polymerase or protease inhibitors. Antimicrob Agents Chemother 2008; 52:1604-1612. (Pubitemid 351614649)
34. Middleton T., He Y., Pilot-Matias T., et al. A replicon-based shuttle vector system for assessing the phenotype of HCV NS5B polymerase genes isolated from patient populations. J Virol Methods 2007; 145:137-145. (Pubitemid 47332699)